NetworkNewsBreaks – India Globalization Capital,
Post# of 435
(Total Views: 760)
Posted On: 08/01/2017 5:56:07 PM
NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Dr. Chuanhai Cao to Medical Research Team
India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Dr. Chuanhai Cao has joined its medical research team as a key advisor. “The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials,” Ram Mukunda, CEO of IGC, noted in the news release. “Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for an Investigational New Drug (IND) application with the FDA. Dr. Cao is the perfect researcher to assist us in moving our THC-based Alzheimer’s treatment into trials and potentially into a blockbuster product.” Cao currently serves as associate professor of pharmaceutical sciences at the University of South Florida’s College of Pharmacy. Additionally, he has joint appointments as associate professor at USF’s Department of Neurology at the College of Medicine and the Department of CMMB at the College of Arts and Sciences.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Dr. Chuanhai Cao has joined its medical research team as a key advisor. “The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials,” Ram Mukunda, CEO of IGC, noted in the news release. “Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for an Investigational New Drug (IND) application with the FDA. Dr. Cao is the perfect researcher to assist us in moving our THC-based Alzheimer’s treatment into trials and potentially into a blockbuster product.” Cao currently serves as associate professor of pharmaceutical sciences at the University of South Florida’s College of Pharmacy. Additionally, he has joint appointments as associate professor at USF’s Department of Neurology at the College of Medicine and the Department of CMMB at the College of Arts and Sciences.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)IGC Pharma Inc. (IGC) Stock Research Links
Scroll down for more posts ▼